Patents Assigned to VIB VZW
-
Patent number: 11466270Abstract: The present application relates to the field of inflammatory diseases, particularly to inflammatory diseases characterized by an M1 macrophage response, even more particularly to sepsis and to Trypanosoma infection. The invention provides substances modulating miR210 expression and/or activity, in particular RNA molecules inhibiting miR210 expression and/or activity and medical uses of these miR210 inhibitors. Methods are disclosed to screen for medicaments for treating sepsis.Type: GrantFiled: October 3, 2017Date of Patent: October 11, 2022Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R & DInventors: Massimiliano Mazzone, Anne-Theres Henze
-
Patent number: 11421209Abstract: The present application relates to the field of glyco-engineering, more specifically to glyco-engineering of Fc-containing molecules, such as antibodies. It is shown herein that Fc-containing molecules with a specific glycosylation pattern have a considerably longer circulating half-life in vivo, without having an altered binding affinity for their respective antigen. This has therapeutic implications in reducing the frequency with which these molecules need to be administered, without affecting therapeutic efficacy. Also, cells are provided that can produce the Fc molecules with the desired glycosylation pattern.Type: GrantFiled: October 5, 2018Date of Patent: August 23, 2022Assignees: VIB VZW, Universiteit GentInventors: Nico L. M. Callewaert, Francis Santens
-
Publication number: 20220259677Abstract: The present application relates to the field of cancer, particular to hypoxic tumors. It was found that hypoxia is an important driver for hypermethylation of (promoters of) tumor suppressor genes. As this hypermethylation is a stable signature that is also present in circulating tumor DNA in peripheral blood, detecting this methylation pattern is a surrogate marker for tumor hypoxia. This can be used to adapt therapy as well.Type: ApplicationFiled: April 25, 2022Publication date: August 18, 2022Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Life Sciences Research Partners VZWInventors: Diether LAMBRECHTS, Bernard THIENPONT
-
Patent number: 11396532Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.Type: GrantFiled: May 4, 2020Date of Patent: July 26, 2022Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIERInventors: Jan Tavernier, Jennyfer Bultinck, Frank Peelman, Gilles Uze
-
Patent number: 11384154Abstract: The present invention relates, in part, to chimeric proteins comprising at least one targeting moiety that recognizes and binds SIRP1? and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.Type: GrantFiled: February 5, 2018Date of Patent: July 12, 2022Assignees: Orionis Biosciences BV, VIB VZW, Universiteit GentInventors: Nikolai Kley, Jan Tavernier
-
Patent number: 11377484Abstract: The present invention relates to the field of bacterial Surface (S)-layer proteins, in particular to compounds capable of disrupting the bacterial S-Layer, specifically the S-Layer of Bacillus anthracis. More particularly, the invention provides for single domain antibodies for diagnosis and treatment of infection caused by pathogens with an S-Layer, in particular of Bacillus anthracis infection. The invention relates to S-Layer protein binding agents inhibiting bacterial growth and interrupting S-Layer assembly, useful in the treatment of bacterial infection, more specifically treatment of anthrax disease.Type: GrantFiled: October 2, 2018Date of Patent: July 5, 2022Assignees: VIB VZW, Vrij Universiteit BrusselInventors: Han Remaut, Antonella Fioravanti
-
Patent number: 11358997Abstract: The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.Type: GrantFiled: August 14, 2018Date of Patent: June 14, 2022Assignees: VIB VZW, Universiteit Gent, Centre National De La Recherche Scientifique, Université De Montpellier, Centre Hospitalier Regional Universitaire de MontpellierInventors: Jan Tavernier, Jennyfer Bultinck, Sarah Gerlo, Gilles Uze, Franciane Paul, Yann Bordat
-
Patent number: 11352422Abstract: Agents that specifically bind to an opioid receptor in a conformationally specific way can be used to induce a conformational change in the receptor. Such agents have therapeutic applications and can be used in X-ray crystallography studies of the receptor. Such agents can also be used to improve drug discovery via compound screening and/or structure-based drug design.Type: GrantFiled: March 15, 2019Date of Patent: June 7, 2022Assignees: VIB VZW, Vrije Univeriteit Brussel, Board of Trustees Leland Stanford Jr UniversityInventors: Jan Steyaert, Toon Laeremans, Els Pardon, Brian Kobilka, Aashish Manglik
-
Patent number: 11346848Abstract: The present invention relates to the field of neurodegenerative diseases. More specifically, the present invention relates to a screening assay to produce compounds stabilizing the gamma-secretase enzyme substrate complex, thereby increasing gamma-secretase processivity while attenuating the release of longer A? peptides. More specifically, gamma-secretase stabilizing compounds increase thermostability of the enzyme/substrate complexes acting in the sequential ?-secretase processing of APP, to result in reduced amyloidogenic A? production, thereby preventing Alzheimer disease.Type: GrantFiled: January 10, 2018Date of Patent: May 31, 2022Assignees: VIB VZW, Katholieke Universiteit Leuven, KU Leuven R&DInventors: Bart De Strooper, Lucia Chávez Gutiérrez, Maria Szaruga
-
Publication number: 20220162264Abstract: The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.Type: ApplicationFiled: March 18, 2021Publication date: May 26, 2022Applicants: Oxford Nanopore Technologies Limited, VIB VZW, Vrije Universiteit BrusselInventors: Han Remaut, Sander Van Der Verren, Nani Van Gerven, Lakmal Jayasinghe, Elizabeth Jayne Wallace, Pratik Raj Singh, Richard George Hambley, Michael Jordan, John Joseph Kilgour
-
Patent number: 11339124Abstract: The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and/or oxytosis for the treatment of stroke, myocardial infarction, diabetes, sepsis, the prevention of transplant rejection, neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, dementia with Lewy bodies and Friedreich's ataxia. The present invention further relates to pharmaceutical compositions of these compounds and discloses methods for making the compounds and the corresponding intermediate.Type: GrantFiled: February 5, 2019Date of Patent: May 24, 2022Assignees: UNIVERSITEIT ANTWERPEN, VIB VZW, UNIVERSITEIT GENTInventors: Peter Vandenabeele, Tom Vanden Berghe, Koen Augustyns, Sam Hofmans, Pieter Van Der Veken, Lars Devisscher
-
Patent number: 11332526Abstract: The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.Type: GrantFiled: July 16, 2018Date of Patent: May 17, 2022Assignees: VIB VZW, Katholieke Univeriteit Leuven, K.U. Leuven R&DInventors: Patrik Verstreken, Joseph McInnes, Lujia Zhou
-
Patent number: 11293012Abstract: The present application relates to the field of glyco-engineering and, more specifically, to eukaryotic cells wherein both an endoglucosaminidase is present and made deficient in UDP-galactose 4-epimerase (GalE). Typically, a glycoprotein is also present in the cells. These cells can be used to deglycosylate or partly deglycosylate the (exogenous) glycoprotein, in particular, without the need for adding an extra enzyme. Methods are also provided for the application of these cells in protein production.Type: GrantFiled: July 8, 2016Date of Patent: April 5, 2022Assignees: VIB VZW, Universiteit GentInventors: Nico Callewaert, Leander Meuris, Francis Santens
-
Publication number: 20220056517Abstract: A system for characterising a target polynucleotide, the system comprising a membrane and a pore complex; wherein the pore complex comprises: (i) a nanopore located in the membrane, and (ii) an auxiliary protein or peptide attached to the nanopore; wherein the nanopore and the auxiliary protein or peptide together form a continuous channel across the membrane, the channel comprising a first constriction region and a second constriction region; wherein the first constriction region is formed by a portion of the nanopore, and wherein the second constriction region is formed by at least a portion of the auxiliary protein or peptide.Type: ApplicationFiled: November 7, 2019Publication date: February 24, 2022Applicants: Oxford Nanopore Technologies Limited, VIB VZW, Vrije Universiteit BrusselInventors: Han Remaut, Sander Van Der Verren, Nani Van Gerven, Lakmal Nishantha Jayasinghe, Elizabeth Jayne Wallace, Pratik Raj Singh, Richard George Hambley, Michael Robert Jordan, John Joseph Kilgour, Andrew John Heron
-
Patent number: 11248057Abstract: The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases.Type: GrantFiled: March 7, 2017Date of Patent: February 15, 2022Assignees: VIB VZW, Universiteit GentInventors: Jan Tavernier, Anje Cauwels, José Van Der Heyden
-
Patent number: 11246911Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.Type: GrantFiled: February 6, 2018Date of Patent: February 15, 2022Assignees: VIB VZW, Centre National de la Recherche Scientifique, Univeriteit Gent, Universite de MontpellierInventors: Jan Tavernier, Jose Van Der Heyden, Genevieve Garcin, Gilles Uze, Yann Bordat
-
Patent number: 11242511Abstract: The disclosure relates to a cytoplasmic protein complex comprising: (a) a first recombinant fusion protein comprising a kinase, fused to a first interaction polypeptide; and (b) a second recombinant fusion protein comprising a domain comprising a reporter phosphorylation site, whereby the domain is fused to a second interaction polypeptide. The disclosure relates further to a method to detect compound-compound-interaction using the cytoplasmic protein complex, and to cells comprising such cytoplasmic protein complex.Type: GrantFiled: February 25, 2019Date of Patent: February 8, 2022Assignees: VIB VZW, Universiteit GentInventors: Jan Tavernier, Samuel Lievens
-
Patent number: 11236166Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.Type: GrantFiled: February 6, 2017Date of Patent: February 1, 2022Assignees: Orionis Biosciences BV, VIB VZW, UNIVERSITEIT GENTInventors: Nikolai Kley, Jan Tavernier, Anje Cauwels, Sarah Gerlo
-
Patent number: 11237174Abstract: The disclosure relates to a virus-like particle in which a protein complex is entrapped, ensuring the formation of the protein complex under physiological conditions, while protecting the protein complex during purification and identification. The disclosure further relates to the use of such virus-like particle for the isolation and identification of protein complexes.Type: GrantFiled: October 14, 2019Date of Patent: February 1, 2022Assignees: VIB VZW, Universiteit GentInventors: Jan Tavernier, Sven Eyckerman
-
Patent number: 11236141Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.Type: GrantFiled: May 12, 2017Date of Patent: February 1, 2022Assignees: Orionis Biosciences BV, VIB VZW, Universiteit GentInventors: Nikolai Kley, Jan Tavernier, Frank Peelman